These injections, known as Semaglutide (sold under names like Ozempic and Wegovy), are praised as a groundbreaking solution in the fight against obesity.
But here’s a twist you might not expect – experts are now warning that these jabs could lead to a serious eye condition, potentially causing blindness.
Researchers from the US have discovered that people with diabetes taking Semaglutide are four times more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION), an alarming eye condition.
Even more concerning, those who are overweight or obese and on the medication are seven times more likely to develop NAION compared to those on other weight-loss drugs.
This condition, often referred to as an “eye stroke,” can result in sudden vision loss in one eye without any pain.
Professor Joseph Rizzo, an ophthalmology expert at Harvard Medical School, shared his insights: “While these drugs have significant benefits, discussions between patients and doctors should include the potential risk of NAION, especially for those with other optic nerve issues like glaucoma.”
It’s important to note, though, that NAION is relatively rare, affecting about one in 10,000 people.
Understanding NAION
NAION happens when the blood vessels supplying the optic nerve get blocked, depriving it of oxygen and causing damage.
Unlike other strokes, NAION doesn’t come with weakness, numbness, or speech loss.
Patients typically notice a sudden loss of vision in one eye upon waking up, and unfortunately, there are no current treatments to restore the lost vision.
Harvard researchers began looking into this potential link after three patients on Semaglutide were diagnosed with NAION within a week.
They analyzed data from over 16,000 patients treated at Massachusetts Eye and Ear hospital over six years.
Their findings revealed that among diabetic patients, those on Semaglutide had a significantly higher incidence of NAION compared to those on other diabetes medications.
A Call for Caution
Although the number of NAION cases was relatively small, the findings are significant enough to warrant further study.
Professor Rizzo emphasized the importance of including this information in patient-doctor discussions, especially for those with existing optic nerve issues.
Similarly, Professor Graham McGeown from Queen’s University Belfast called for larger studies to further explore this association.
Balancing Risks and Benefits
The manufacturer of Ozempic and Wegovy, Novo Nordisk, has been contacted for their comments.
Meanwhile, health officials are urging caution.
Professor Sir Stephen Powis of NHS England warned against using these drugs as a quick fix for weight loss, highlighting that they should be reserved for treating obesity or diabetes.
The Bigger Picture
While the injections have shown promise in helping people lose weight and manage diabetes, it’s crucial to be aware of potential side effects, which can range from nausea and headaches to more severe issues like hair loss and, as newly highlighted, possible vision loss.
As the UK grapples with high rates of obesity, experts stress the importance of balanced diet and exercise as key components in tackling this epidemic.
So, next time you hear about the wonders of weight loss jabs, remember the full picture – the benefits, the risks, and the importance of making informed decisions with your healthcare provider.
Health News
Mine Crypto. Earn $GOATS while it is free! Click Here!!